Lead Product(s) : VAR002
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
VARIANT Gets EMA Positive Feedback for Innovative Gene Therapy VAR002
Details : VAR002 is a recombinant adeno-associated viral (rAAV) vector initially developed to treat Leber's congenital amaurosis, Retinitis pigmentosa, and Cone-rod dystrophy due to a mutation in the CRX gene.
Product Name : VAR002
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 03, 2025
Lead Product(s) : VAR002
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NCX 1728
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Glaukos
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement
Details : Under the license agreement, Glaukos will fund and conduct NCX 1728 preclinical research activities evaluating it in glaucoma (including neuroprotection) and other retinal diseases.
Product Name : NCX 1728
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 23, 2024
Lead Product(s) : NCX 1728
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Glaukos
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : BO-001
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : HTL Biotechnology
Deal Size : $6.9 million
Deal Type : Financing
BIOPHTA Raises 6.5M Euros Funding to Transition its New Standard of Care for Eye Diseases
Details : The financing aims to fund the first-in-human trial of breakthrough topical ophthalmic investigational product BO-001 for the the treatment of glaucoma.
Product Name : BO-001
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 06, 2024
Lead Product(s) : BO-001
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : HTL Biotechnology
Deal Size : $6.9 million
Deal Type : Financing
Lead Product(s) : BO-001
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : UI Investissement
Deal Size : $6.9 million
Deal Type : Financing
BIOPHTA Raises €6.5M For Eye Disease Therapy Clinical Transition
Details : The financing aims to fund the first-in-human trial of breakthrough topical ophthalmic investigational product BO-001 for the the treatment of glaucoma.
Product Name : BO-001
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 06, 2024
Lead Product(s) : BO-001
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : UI Investissement
Deal Size : $6.9 million
Deal Type : Financing
Lead Product(s) : PST-809
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Pureos Bioventures
Deal Size : Inapplicable
Deal Type : Inapplicable
PulseSight Launches to Advance Non-Viral Gene Therapies for Severe Retinal Diseases
Details : PST-809, is a potential first-in-class therapy for wet age-related macular degeneration that comprises a dual-gene plasmid encoding for anti-VEGF, aflibercept, together with decorin.
Product Name : PST-809
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 27, 2024
Lead Product(s) : PST-809
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Pureos Bioventures
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Macuneos
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : BPI
Deal Size : $1.1 million
Deal Type : Funding
Details : Macuneos (BIO201) is an orally administered small molecule in development for the treatment of diseases of the retina, or retinopathies. Biophytis has completed preclinical cellular and animal studies of Macuneos (BIO201) for the treatment of retinopathi...
Product Name : BIO201
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
April 29, 2021
Lead Product(s) : Macuneos
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : BPI
Deal Size : $1.1 million
Deal Type : Funding
Lead Product(s) : SPVN06
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SPVN06 uses a gene therapy-based approach independent of mutated genes and by a single subretinal injection of proprietary neurotrophic factors, aims at stopping and preventing the degeneration of photoreceptors leading to blindness.
Product Name : SPVN06
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 30, 2020
Lead Product(s) : SPVN06
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable